BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 17054106)

  • 21. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
    Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
    J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.
    Fiegl M; Stauder R; Steurer M; Mian M; Hopfinger G; Brychtova Y; Skrabs C; Zabernigg A; Schmid F; Haslbaur F; Winder G; Walder A; Lang A; Voskova D; Greil R; Mayer J; Gastl G;
    Ann Hematol; 2014 Feb; 93(2):267-77. PubMed ID: 24292560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.
    Fiegl M; Falkner F; Steurer M; Zojer N; Hopfinger G; Haslbauer F; Winder G; Voskova D; Andel J; Lang A; Brychtova Y; Mayer J; Greil R; Gastl G; ; ;
    Ann Hematol; 2011 Sep; 90(9):1083-91. PubMed ID: 21350830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
    Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
    J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
    Ferrajoli A; O'Brien SM; Cortes JE; Giles FJ; Thomas DA; Faderl S; Kurzrock R; Lerner S; Kontoyiannis DP; Keating MJ
    Cancer; 2003 Aug; 98(4):773-8. PubMed ID: 12910522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
    Fiegl M; Falkner A; Hopfinger G; Brugger S; Zabernigg A; Bauer F; Haslbauer F; Demirtas D; Grossschmidt P; Tatzreiter G; Gastl G; Greil R;
    Cancer; 2006 Nov; 107(10):2408-16. PubMed ID: 17054106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alemtuzumab for B-cell chronic lymphocytic leukemia.
    Robak T
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alemtuzumab in chronic lymphocytic leukemia.
    James DF; Kipps TJ
    Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alemtuzumab: what is the secret to safe therapy?
    Elter T; Hallek M; Montillo M
    Clin Adv Hematol Oncol; 2011 May; 9(5):364-73. PubMed ID: 21685865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
    Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
    Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The evolving role of alemtuzumab in management of patients with CLL.
    Faderl S; Coutré S; Byrd JC; Dearden C; Denes A; Dyer MJ; Gregory SA; Gribben JG; Hillmen P; Keating M; Rosen S; Venugopal P; Rai K
    Leukemia; 2005 Dec; 19(12):2147-52. PubMed ID: 16239912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies in the management of alemtuzumab-related side effects.
    Osterborg A; Karlsson C; Lundin J; Kimby E; Mellstedt H
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S29-35. PubMed ID: 16720201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Robak T
    BioDrugs; 2005; 19(1):9-22. PubMed ID: 15691213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia.
    Rai KR
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S15-22. PubMed ID: 16720199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody therapy for chronic lymphocytic leukemia: a promising new modality.
    Lin TS; Moran M; Lucas M; Waymer S; Jefferson S; Fischer DB; Grever MR; Byrd JC
    Hematol Oncol Clin North Am; 2004 Aug; 18(4):895-913, ix-x. PubMed ID: 15325705
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.